Form 4: Arcturus Therapeutics Executive Sells 12,000 Shares Under 10b5-1 Plan

Arcturus Therapeutics' Chief Scientific Officer & COO, Pad Chivukula, sold 12,000 shares of common stock at an average price of $20.7601 on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Pad Chivukula, the Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc., sold 12,000 shares of common stock on October 15, 2024.
• The sale was executed under a Rule 10b5-1 trading plan.
• The weighted average price for the shares sold was $20.7601.
• The sale prices ranged from $20.03 to $21.12 per share.
• Following the transaction, Chivukula directly owns 435,334 shares of Arcturus Therapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price upon request.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating an insider stock sale. The use of a 10b5-1 plan suggests the sale was pre-planned. The sentiment is neutral as it's a routine disclosure.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates